Avanos Medical Stock Forecast, Price & News

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVNS stock has increased by 49.3% and is now trading at $43.30.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Avanos Medical or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Avanos Medical a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Avanos Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Avanos Medical.

Avanos Medical, Inc. (NYSE:AVNS) posted its quarterly earnings results on Tuesday, November, 3rd. The company reported $0.21 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.10 by $0.11. The company had revenue of $186 million for the quarter, compared to analysts' expectations of $165.87 million. Avanos Medical had a return on equity of 3.20% and a net margin of 1.93%. The business's revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 EPS.
View Avanos Medical's earnings history.

5 equities research analysts have issued twelve-month price targets for Avanos Medical's stock. Their forecasts range from $30.00 to $47.00. On average, they anticipate Avanos Medical's stock price to reach $35.00 in the next year. This suggests that the stock has a possible downside of 19.2%.
View analysts' price targets for Avanos Medical.

Avanos Medical saw a drop in short interest during the month of October. As of October 15th, there was short interest totaling 1,960,000 shares, a drop of 17.6% from the September 30th total of 2,380,000 shares. Based on an average daily volume of 245,100 shares, the days-to-cover ratio is presently 8.0 days. Currently, 4.2% of the company's stock are sold short.
View Avanos Medical's Short Interest.

Some companies that are related to Avanos Medical include Wound Management Technologies (WNDM), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC), Sientra (SIEN), United Health Products (UEEC), Sanara MedTech (SMTI), Surgalign (SRGA), Alpha Pro Tech (APT), Alpha Pro Tech (APT), Lakeland Industries (LAKE), Milestone Scientific (MLSS) and Milestone Scientific (MLSS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Honeywell International (HON), Pfizer (PFE), The Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Avanos Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.76%), Champlain Investment Partners LLC (7.07%), Victory Capital Management Inc. (4.30%), State Street Corp (3.60%), Confluence Investment Management LLC (1.07%) and Neuberger Berman Group LLC (1.03%). Company insiders that own Avanos Medical stock include Gary Blackford and Joseph Fralin Woody.
View institutional ownership trends for Avanos Medical.

AVNS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Employees Retirement System of Texas, Confluence Investment Management LLC, Federated Hermes Inc., Morgan Stanley, Charles Schwab Investment Management Inc., and Neuberger Berman Group LLC.
View insider buying and selling activity for Avanos Medical.

AVNS stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Assenagon Asset Management S.A., JPMorgan Chase & Co., Millrace Asset Group Inc., Great West Life Assurance Co. Can, Champlain Investment Partners LLC, Pacer Advisors Inc., and Sei Investments Co.. Company insiders that have bought Avanos Medical stock in the last two years include Gary Blackford, and Joseph Fralin Woody.
View insider buying and selling activity for Avanos Medical.

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVNS stock can currently be purchased for approximately $43.30.

Avanos Medical has a market capitalization of $2.07 billion and generates $697.60 million in revenue each year. The company earns $-45,900,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. Avanos Medical employs 4,700 workers across the globe.

The official website for Avanos Medical is avanos.com.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at 844-428-2667 or via email at [email protected]